Kyowa Kirin Co. Ltd
Kyowa Kirin Co., Ltd. engages in the research, development, manufacture, import/export, and market of pharmaceuticals products worldwide. The company offers Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; POTELIGEO for the treatment of cutaneous T-cell lymphoma; Nouriast/Nourianz, an adenosine A2A receptor antagonist; G-LASTA, a… Read more
Kyowa Kirin Co. Ltd (KYKOF) - Net Assets
Latest net assets as of December 2025: $894.11 Billion USD
Based on the latest financial reports, Kyowa Kirin Co. Ltd (KYKOF) has net assets worth $894.11 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.11 Trillion) and total liabilities ($214.72 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $894.11 Billion |
| % of Total Assets | 80.64% |
| Annual Growth Rate | 5.95% |
| 5-Year Change | 21.29% |
| 10-Year Change | 48.83% |
| Growth Volatility | 21.27 |
Kyowa Kirin Co. Ltd - Net Assets Trend (1999–2025)
This chart illustrates how Kyowa Kirin Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Kyowa Kirin Co. Ltd (1999–2025)
The table below shows the annual net assets of Kyowa Kirin Co. Ltd from 1999 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $894.11 Billion | +5.09% |
| 2024-12-31 | $850.81 Billion | +1.72% |
| 2023-12-31 | $836.42 Billion | +9.65% |
| 2022-12-31 | $762.83 Billion | +3.48% |
| 2021-12-31 | $737.16 Billion | +5.55% |
| 2020-12-31 | $698.40 Billion | +2.97% |
| 2019-12-31 | $678.25 Billion | +4.41% |
| 2018-12-31 | $649.62 Billion | +5.45% |
| 2017-12-31 | $616.03 Billion | +2.54% |
| 2016-12-31 | $600.74 Billion | -2.30% |
| 2015-12-31 | $614.86 Billion | +1.57% |
| 2014-12-31 | $605.37 Billion | +1.67% |
| 2013-12-31 | $595.41 Billion | +7.11% |
| 2012-12-31 | $555.90 Billion | +2.94% |
| 2011-12-31 | $540.02 Billion | -0.91% |
| 2010-12-31 | $544.99 Billion | +0.86% |
| 2009-12-31 | $540.34 Billion | +110.45% |
| 2007-12-31 | $256.76 Billion | +5.19% |
| 2006-12-31 | $244.08 Billion | -5.21% |
| 2005-12-31 | $257.49 Billion | +8.69% |
| 2004-12-31 | $236.90 Billion | +4.62% |
| 2003-12-31 | $226.43 Billion | +2.69% |
| 2002-12-31 | $220.50 Billion | +3.47% |
| 2001-12-31 | $213.10 Billion | +8.14% |
| 2000-12-31 | $197.06 Billion | -1.00% |
| 1999-12-31 | $199.04 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kyowa Kirin Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 225.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $406.68 Billion | 45.48% |
| Common Stock | $26.77 Billion | 2.99% |
| Other Comprehensive Income | $38.15 Billion | 4.27% |
| Other Components | $422.52 Billion | 47.26% |
| Total Equity | $894.11 Billion | 100.00% |
Kyowa Kirin Co. Ltd Competitors by Market Cap
The table below lists competitors of Kyowa Kirin Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BGC Group Inc.
NASDAQ:BGC
|
$3.46 Billion |
|
DoorDash, Inc.
SA:D2AS34
|
$3.47 Billion |
|
Voestalpine AG
PINK:VLPNF
|
$3.47 Billion |
|
Vietnam Rubber Group Ltd
VN:GVR
|
$3.47 Billion |
|
Allreal Holding
SW:ALLN
|
$3.46 Billion |
|
The Siam Cement Public Company Limited
PINK:SCVPF
|
$3.46 Billion |
|
Zealand Pharma A/S
PINK:ZLDPF
|
$3.46 Billion |
|
Impulsora del Desarrollo y el Empleo en América Latina S.A.B. de C.V
MX:IDEALB-1
|
$3.46 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kyowa Kirin Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 850,811,000,000 to 894,111,532,000, a change of 43,300,532,000 (5.1%).
- Net income of 67,098,500,000 contributed positively to equity growth.
- Dividend payments of 30,908,948,000 reduced retained earnings.
- Share repurchases of 9,008,000 reduced equity.
- Other comprehensive income increased equity by 6,980,261,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $67.10 Billion | +7.5% |
| Dividends Paid | $30.91 Billion | -3.46% |
| Share Repurchases | $9.01 Million | -0.0% |
| Other Comprehensive Income | $6.98 Billion | +0.78% |
| Other Changes | $139.73 Million | +0.02% |
| Total Change | $- | 5.09% |
Book Value vs Market Value Analysis
This analysis compares Kyowa Kirin Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | $448.07 | $14.75 | x |
| 2000-12-31 | $448.35 | $14.75 | x |
| 2001-12-31 | $487.40 | $14.75 | x |
| 2002-12-31 | $505.01 | $14.75 | x |
| 2003-12-31 | $521.54 | $14.75 | x |
| 2004-12-31 | $550.56 | $14.75 | x |
| 2005-12-31 | $602.07 | $14.75 | x |
| 2006-12-31 | $596.59 | $14.75 | x |
| 2007-12-31 | $639.77 | $14.75 | x |
| 2009-12-31 | $938.85 | $14.75 | x |
| 2010-12-31 | $954.55 | $14.75 | x |
| 2011-12-31 | $950.32 | $14.75 | x |
| 2012-12-31 | $1011.56 | $14.75 | x |
| 2013-12-31 | $1084.88 | $14.75 | x |
| 2014-12-31 | $1105.03 | $14.75 | x |
| 2015-12-31 | $1122.58 | $14.75 | x |
| 2016-12-31 | $1096.52 | $14.75 | x |
| 2017-12-31 | $1124.42 | $14.75 | x |
| 2018-12-31 | $1205.21 | $14.75 | x |
| 2019-12-31 | $1258.33 | $14.75 | x |
| 2020-12-31 | $1299.39 | $14.75 | x |
| 2021-12-31 | $1371.43 | $14.75 | x |
| 2022-12-31 | $1419.03 | $14.75 | x |
| 2023-12-31 | $1555.74 | $14.75 | x |
| 2024-12-31 | $1606.65 | $14.75 | x |
| 2025-12-31 | $1708.11 | $14.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kyowa Kirin Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.50%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.49%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 1.24x
- Recent ROE (7.50%) is above the historical average (5.97%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | 5.78% | 3.01% | 0.86x | 2.22x | $-8.23 Billion |
| 2000 | 4.83% | 2.50% | 0.87x | 2.22x | $-10.07 Billion |
| 2001 | 2.62% | 1.46% | 0.88x | 2.03x | $-15.63 Billion |
| 2002 | 3.87% | 2.36% | 0.97x | 1.68x | $-13.42 Billion |
| 2003 | 4.45% | 2.87% | 0.97x | 1.60x | $-12.49 Billion |
| 2004 | 7.62% | 5.00% | 0.96x | 1.59x | $-5.61 Billion |
| 2005 | 6.36% | 4.60% | 0.92x | 1.50x | $-9.31 Billion |
| 2006 | 5.25% | 3.58% | 0.94x | 1.57x | $-11.48 Billion |
| 2007 | 9.23% | 5.99% | 1.00x | 1.55x | $-1.97 Billion |
| 2010 | 4.08% | 5.36% | 0.59x | 1.28x | $-32.22 Billion |
| 2011 | 4.75% | 7.45% | 0.52x | 1.22x | $-28.30 Billion |
| 2012 | 4.36% | 7.26% | 0.49x | 1.22x | $-31.31 Billion |
| 2013 | 5.06% | 8.83% | 0.47x | 1.21x | $-29.35 Billion |
| 2014 | 2.63% | 4.77% | 0.46x | 1.19x | $-44.64 Billion |
| 2015 | 4.84% | 8.17% | 0.51x | 1.17x | $-31.71 Billion |
| 2016 | 3.11% | 5.44% | 0.49x | 1.16x | $-41.41 Billion |
| 2017 | 6.96% | 12.14% | 0.50x | 1.15x | $-18.70 Billion |
| 2018 | 8.38% | 15.70% | 0.47x | 1.14x | $-10.55 Billion |
| 2019 | 9.89% | 21.94% | 0.39x | 1.16x | $-741.00 Million |
| 2020 | 6.73% | 14.77% | 0.40x | 1.15x | $-22.81 Billion |
| 2021 | 7.10% | 14.86% | 0.38x | 1.25x | $-21.37 Billion |
| 2022 | 7.02% | 13.45% | 0.42x | 1.23x | $-22.71 Billion |
| 2023 | 9.71% | 18.36% | 0.43x | 1.23x | $-2.45 Billion |
| 2024 | 7.04% | 12.08% | 0.46x | 1.25x | $-25.21 Billion |
| 2025 | 7.50% | 13.49% | 0.45x | 1.24x | $-22.31 Billion |
Industry Comparison
This section compares Kyowa Kirin Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $580,491,146
- Average return on equity (ROE) among peers: -45.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kyowa Kirin Co. Ltd (KYKOF) | $894.11 Billion | 5.78% | 0.24x | $3.46 Billion |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $14.78 Million | -64.19% | 0.99x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $-241.47K | 0.00% | 0.00x | $603.58K |
| Aurora Cannabis Inc (ACB) | $521.74 Million | -329.21% | 0.78x | $194.64 Million |
| Acreage Holdings Inc (ACRDF) | $494.79 Million | -30.37% | 0.40x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $37.06 Million | 39.05% | 0.16x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $32.70 Million | -18.88% | 0.16x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $21.19 Million | 12.93% | 1.96x | $1.84 |
| Adcock Ingram Holdings Limited (AIHLF) | $4.54 Billion | 14.90% | 0.58x | $85.61 Million |